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Insulin resistance and type 2 diabetes are associated with hepatitis C virus infection. A wealth of clinical and experimental data
suggests that the virus is directly interfering with the insulin signalling in hepatocytes. In the case of at least one viral genotype (the
type 3a), insulin resistance seems to be directly mediated by the downregulation of the peroxisome proliferator-activated receptor
γ. Whether and how this interaction may be manipulated pharmacologically, in order to improve the responsiveness to antivirals
of insulin resistant chronic hepatitis C, patients remain to be fully explored.
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1.Introduction
Hepatitis C virus (HCV) infection is associated with an
increasedriskofdevelopingglucoseintoleranceanddiabetes.
This is in part due to a direct interference of HCV with the
insulin signalling pathway. The mechanisms involved seem
to be HCV genotype-speciﬁc, and this suggests that HCV
may proﬁt from the insulin resistant phenotype to establish
and/or maintain a persistent infection. Since the peroxisome
proliferator-activated receptors (PPARs) are nuclear fac-
tors involved—among others—in the regulation of glucose
homeostasis, the relationship between HCV replication and
protein expression and PPARs has been the focus of some
recent studies. However, the data available so far are quite
scanty and concern only the HCV genotype 3a. In fact,
although most viral genotypes seem to activate members of
thesuppressorsofcytokinesignalling(SOCS)familyinorder
to inhibit insulin signalling, in the case of genotype 3a, some
in vitro observations are consistent with a downregulation
of the PPARγ. If conﬁrmed, these observations may be
relevant to the treatment of chronic hepatitis C, since insulin
resistance is a factor of poor response to antivirals. This
article will brieﬂy review the role of PPARs in insulin
resistance, the interactions between HCV and PPARs, and
their clinical signiﬁcance.
2.PPARs inInsulinResistance andDiabetes
PPARs are the established targets of several classes of drugs
used in the management of the metabolic syndrome, like the
ﬁbrates and the thiazolidindiones. A new class of pan-PPAR
agonists, the glitazars, is presently under investigation. This
article will describe the role and signiﬁcance of PPARα and γ
in glucose metabolism, since the few data from HCV models
have addressed the deregulation of only these two factors. No
data are currently available about the involvement of PPARδ
in the HCV-associated insulin resistance.
PPARα is principally expressed in tissues exhibiting high
rates of β-oxidation such as liver, kidney, heart, and muscle,
and can be activated by dietary fatty acids and eicosanoids
or by speciﬁc drugs such as ﬁbrates. Activation of PPARα
results in increased fatty acid β-oxidation in the liver [1],
increased expression of HDL apolipoproteins Apo A-I and
Apo A-II [2],inhibitedexpressionofApoC-III[3],increased
lipoprotein lipase activity [4], and, therefore, increased
VLDL and remnants clearance. As to insulin resistance,
PPARα seems to improve—indirectly—insulin sensitivity by
increasing hepatic catabolism of lipids, and thus reducing
lipid supply to skeletal muscle [5].
PPARγ is expressed at very high levels in adipose tissue,
and much less in the liver and other organs. Apart from its2 PPAR Research
natural ligands, that is, fatty acids, it is activated by drugs
of the class of thiazolidindiones such as rosiglitazone and
pioglitazone. Hyperglycaemia and hyperlipidaemia in obese
and diabetic animals are improved by pioglitazone through
reduction of both peripheral and hepatic insulin resistance
[6]. In the animal model, treatment with PPARγ agonists
lowers plasma level of free fatty acids and insulin, and
increase the phosphorylation level of Akt at both threonine
308 and serine 473 in the liver and both the adipose
and muscle tissues [7]. This, in turn, is correlated with
tyrosine phosphorylation of insulin receptor β subunit and
insulin receptor substrate-1, and serine phosphorylation of
glycogen synthase kinase-3α/β [7]. Additional hepatic eﬀects
include increased insulin sensitivity via G-protein subunits
downregulation, leading to reduced glucose production by
approximately 30%, accompanied by a signiﬁcant increase of
glucose-induced insulin suppression in β-cells [8].
In addition to the direct eﬀects on factors involved in
lipid and glucose homeostasis, PPARs may have insulin sen-
sitizing eﬀects via their anti-inﬂammatory activity. PPARγ
reduces the expression of activator protein-1 and nuclear
factor-κB ,r e d u c e ss p e c i ﬁ cs u b s e t so fl i p o p o l y s a c c h a r i d e
and interferon (IFN) target genes in macrophages [9, 10],
and reduces tissue expression of tumor necrosis factor-α
(TNFα), IFN-γ, C-reactive protein, and induction of other
proinﬂammatory cytokines, including hepatocytes [11].
Thus, treatment with PPARs agonists results in improved
insulin sensitivity via diverse mechanisms, both direct and
indirect, and both at the level of the liver and at the level of
extrahepatic tissues.
3.HepatitisCVirusInfectionand
InsulinResistance
Insulin resistance and type 2 diabetes are common compli-
cations of all liver diseases, especially at the advanced stage.
In the case of HCV infection, however, both clinical and
experimental observations suggest that HCV may directly
interfere with glucose homeostasis. Cross-sectional, case-
control, and longitudinal studies—performed in both large
unselected cohorts and in patients with liver or kidney
transplantation—have suggested that type 2 diabetes may be
more prevalent in chronic hepatitis C patients, especially if
aged more than 40 and if other major risk factors of glucose
intolerance are present [12]. The confounding eﬀect of liver
disease stage can be eliminated if studies are conducted in
patients with little or no liver ﬁbrosis, and if—instead of
looking for cases with overt diabetes—glucose homeostasis
is assessed as level of insulin sensitivity. Hui et al. [13]f o u n d
that 121 HCV-infected patients with stage 0 or 1 liver ﬁbrosis
had higher levels of HOMA scorecompared with 137 healthy
volunteers matched by sex, body mass index, and waist-to-
hip ratio. This work proved that HCV may induce insulin
resistance at early stages of liver diseases, and provided, in
addition, the ﬁrst evidence that this eﬀect may be due to
genotype-speciﬁc sequences.
Somerecentworksuggestsa trendbetween HCV replica-
tive level and level of insulin resistance [14]. The low-level
correlation may be due to the fact that the global level of
insulin resistance is likely to depend on the contribution
from the adipose tissue and the muscle, two extrahepatic
compartments that are not infected by HCV.
The eﬀect of antiviral therapy is another classical way to
prove an association between infection and disease. Romero-
G´ omez et al. have shown that both the level of insulin resis-
tance [15] and the incidence of ex novo glucose intolerance
over time [16] are reduced after successful therapy in chronic
hepatitis C patients, whereas no improvement is observed in
nonresponders.However,independentconﬁrmationofthese
observations is warranted.
The association between HCV and insulin resistance
has noteworthy consequences, clinically and conceptually.
From the clinical standpoint, insulin resistance accelerates
ﬁbrogenesis [13, 17–19] and impairs response to IFN-α-
based antiviral therapy [15, 20, 21]. In addition, HCV
infection is an interesting example of insulin resistance
not necessarily associated with other components of the
metabolic syndrome, thus providing the framework for
longitudinal studies on speciﬁc risk assessment. Last, but not
least, the question arises what may be the advantage for HCV
to increase insulin resistance; it is apparent that all HCV
genotypes studied so far induce insulin resistance, albeit to
ad i ﬀerent extent [13, 14], suggesting some evolutionary
constraints aimed at maintaining the insulin-resistant phe-
notype despite the viral genome sequence divergence over
time.
Since HCV appears to directly interfere with the glu-
cose homeostasis, several studies have tried to analyze in
detail the potential interactions between viral products
and insulin signalling. Experimental data suggest a direct
interference of HCV with the insulin signalling cascade via
proteasome degradation of the insulin receptor substrates -
1 and -2 [22, 23]. HCV may also impair insulin signalling
transduction indirectly, that is, through increased levels of
proinﬂammatory cytokines such as TNF-α [24, 25]. The
interference with the insulin signalling seems to proceed
via HCV genotype speciﬁc mechanisms (see below) and
insulin resistance levels vary according to the infecting HCV
genotype, although all genotypes induce insulin resistance.
Interestingly, intracellular factors dysregulated by HCV and
responsible for the insulin resistant phenotype may play
promiscuous eﬀects as they are also involved in regulating
IFN-α signalling. These factors include some members of the
suppressor of cytokine signalling (SOCS) family [22, 23, 26]
and the protein phosphatase 2A [27]. Thus, modulating the
levelsand/ortheactivityofthesefactorsmaynotonlyreverse
hepatic insulin resistance but also help establishing the IFN-
α-induced antiviral state at the site of HCV replication. This
is one of the reasons for trying to restore insulin sensitivity
in chronic hepatitis C patients failing to respond to therapy
(see below).
4. HCVInfection andPPARs Expression
Very little data is available concerning the interaction
between HCV products and PPARs expression (Figure 1).
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Figure 1: Reported eﬀects of HCV on some of the relevant
physiological functions of PPARα and PPARγ. The inhibitory eﬀect
on PPARγ has been described only for the genotype 3a. For further
explanations, please refer to the text.
cells transfected with the HCV genotype 3 core encoding
sequence,andwasfoundsigniﬁcantlydecreasedcomparedto
untransfected cells. No changes were observed in cells trans-
fected with the core protein 1b [28]. Incidentally, PPARα was
undetectable, even in untransfected cells, precluding further
evaluations of an interaction with HCV, if any.
Cellstransfectedwiththegenotype3ahadbothincreased
content of triglycerides [29]a n dr e d u c e dl e v e l so fI R S - 1 ,
leading to insulin resistance, as measured by reduced Akt
phosphorylation following incubation with insulin [23]. The
role of PPARγ in HCV 3a-associated insulin resistance in
vitro was further assessed by treating transfected cells with
aP P A R γ agonist, rosiglitazone. Both IRS-1 protein and
insulin-stimulatedAktphosphorylationlevelsincreasedafter
treatmentwithrosiglitazone ofcellstransfectedwiththecore
protein 3a. The recovery of the IRS-1 protein expression
and Akt phosphorylation levels was, however, rather modest,
that is, about 20% and 26%, respectively [23]. Additional
recovery of both IRS-1 level and Akt activation was obtained
by inhibiting SOCS-7 upregulation induced by the same
v i r a lg e n o t y p ei nt h i sm o d e l[ 23]. Although cells expressing
the HCV core 1b had reduced IRS-1 content and insulin
resistance, the eﬀect seemed to be mediated by both SOCS-
and PPARγ-independent mechanisms. Thus, based on this
isolated observation, it seems that PPARγ downregulation
may be responsible, at least in part, for the insulin resistance
observed in vitro upon expression of HCV genotype 3a core
protein expression.
By analyzing total RNA extracted from the liver of
chronic hepatitis C patients, de Gottardi et al. found that the
transcription level of both PPARα and PPARγ was decreased
in genotype 3 infection as compared to genotype 1 [28].
When patients were stratiﬁed according to the presence
of steatosis, PPARα and γ mRNA were reduced only in
steatotic livers from patients infected with genotype 1. In
those with genotype 3, both PPAR mRNA levels were always
low, independently of the presence of steatosis. In this study,
the two groups of patients with genotype 3 and 1 were
comparable as to gender distribution, age, BMI, liver disease
activity, and ﬁbrosis stage. However, in this study, a direct
correlation between PPARs levels and IR was not evaluated.
ThelevelofPPARαmRNAhasbeenmeasuredintheliver
ofchronichepatitisCpatientsalsoinanotherstudy[30],and
found to be profoundly suppressed (about 85% compared
to control livers). The inhibition of PPARα was paralleled
by a signiﬁcant decrease of the carnitine palmitoyl acyl-CoA
transferase 1 mRNA, a key enzyme in the mitochondrial β-
oxidation of fatty acids, and conﬁrmed in an in vitro model
expressingtheHCVcoreprotein[30].Theseauthorsfocused
their discussion on the role of PPARα as anti-inﬂammatory
mediator, and on the consequences of its suppression in the
pathogenesis of hepatitis C. It is important to remember that
the impaired transcriptional activity of PPARα associated
with HCV infection may indirectly worsen IR via increased
expression of TNF-α; thus, the role of inﬂammation in the
pathogenesisofHCV-associatedIRshouldnotbeoverlooked
[31]. On the contrary, it is unlikely that HCV-induced
steatosis, due to decreased expression of PPARα and several
other mechanisms [32], may aggravate insulin resistance,
since the latter has been convincingly shown to precede
steatosis, and not vice versa [33].
5. Perspectivesfor Treatment
As said above, insulin resistance reduces the rate of response
to antivirals in chronic hepatitis C [15, 20, 21]. A sustained
virological response (SVR) was observed in 23 of 70 (32.8%)
of patients with genotype 1 and insulin resistance (i.e., with
aH O M A> 2) versus 26 of 43 (60.5%) of genotype 1
patients without insulin resistance (P = .007) [15]. These
ﬁndings were independently conﬁrmed [20] and extended
to nonresponders with genotypes 2 and 3 [21]. Thus, it
was suggested that insulin resistance should be corrected
in patients with chronic hepatitis C not responding to
IFN-α-based treatment, in order to improve response upon
retreatment. The modalities of this intervention, however,
have not been established. In addition, the optimal HOMA-
IR score to be reached has not been identiﬁed.
A recent prospective, multicenter study aimed at inves-
tigating the eﬃcacy and safety of the insulin-sensitizer
pioglitazone, 15mgQD, added to the pegylated IFN-α2a,
180μgQW/ribavirin, 1000–1200mgQD combination ther-
apy in chronic hepatitis C patients who were previously
nonresponders to a pegylated IFN-α/ribavirin combination
without the insulin sensitizer [34].Allpatients had a baseline
HOMA > 2 as additional inclusion criterion, because this
was the threshold discriminating responders from non-
responders in previous works [16, 21]. Diabetic patients
were however excluded. Unfortunately, none of the ﬁrst ﬁve
patients enrolled into the trial had a satisfactory virological
response after 12 weeks of retreatment, despite the fact that
inatleastthreeofthemtheinsulinresistancescoreimproved,
and thus the study was prematurely terminated [34].
Additional data on this topic have been presented at the
2008 annual meeting of the American Association for the
Study of Liver Diseases. In an interim analysis of a clinical
trial, 30mgQD of pioglitazone were given for four weeks4 PPAR Research
as monotherapy and then added for the ﬁrst four weeks of
a standard therapy of treatment-na¨ ıve, nondiabetic chronic
hepatitis C patients. The authors showed that the triple reg-
imen containing pioglitazone increased signiﬁcantly the rate
of virological response after 4 weeks of therapy compared
to pegylated IFN-α/ribavirin combination [35]. Long-term
data are eagerly awaited. However, in another randomized,
double-blind, placebo-controlled study, adding pioglitazone
30mgQD simultaneously to the standard of care (i.e.,
without a preceding administration as monotherapy) clearly
increased the on-treatment virological response, but failed
to increase the sustained virological response after the end
of treatment [36]. Additional studies evaluating diﬀerent
schedules are clearly warranted. This approach, however,
should also take into consideration the known eﬀects of
PPARagonistsonserumlipidproﬁleandtheirpotentialcon-
sequences on the HCV life cycle. HCV circulates bound to
lipoproteinsincomplexesknownaslipoviroparticles[37].As
a result, HCV entry into hepatocytes appears to be mediated
and facilitated, among others, by the LDL receptor [38]. In
keeping with this, at least two recent studies have suggested
that baseline LDL-associated cholesterol levels may aﬀect
response to antiviral therapy [39, 40]. In fact, higher levels of
cholesterol- and ApoB-rich lipoproteins could facilitate viral
clearance by impeding HCV interaction with cell surface
receptors. Thus, drugs like thiazolidinediones that modify
the circulating lipoprotein proﬁle may have unexpected—
and potentially unwanted—eﬀects on the HCV life cycle. On
the other hand, in addition to lipid-lowering eﬀects, PPARα
agonists have been shown to decrease also the expression
of the LDL receptor in experimental models [41]. This may
oﬀset the untoward eﬀect on lipoproteins by impairing HCV
entry into target cells. Although highly speculative, these
hypotheses deserve being appropriately evaluated in clinical
trials.
Modulating the levels and/or the activity of intracellular
factors involved in HCV-induced insulin resistance may
not only reverse hepatic insulin resistance but also help
establishing the IFN-α-induced antiviral state at the very site
of HCV replication.
However, speciﬁc inhibitors of SOCS family members
and of the protein phosphatase 2A are either not suitable
for in vivo administration or toxic. Alternatively, increasing
insulin sensitivity may be achieved by modulating serum
levels of speciﬁc cytokines, such as TNF-α, associated with
insulin resistance [24, 25], but the administration of anti-
TNF-α antibodies to chronic hepatitis C patients may
be risky [42]. Insulin sensitizers may also inhibit HCV
replication by decreasing serum free fatty acids ﬂow to
hepatocytes; saturated and monounsaturated free fatty acids
have indeed been shown to stimulate HCV replication in an
in vitro model [43].
Thus, although increasing insulin sensitivity may be a
rational option in chronic hepatitis C patients not respond-
ing to current combination therapy, more work is warranted
to identify the appropriate treatment schedule. It is not clear
whether the best approach would be using a thiazolidin-
diones, activating PPARs, or a biguanide such as metformin,
whose mechanism of action is speciﬁcally directed on the
hepatic AMP-activated protein kinase [44]. Another major
issue concerns the treatment schedule. It is unclear whether
one should start the antiviral retreatment together with the
insulin sensitizer or only once the HOMA-IR score has
decreased to a level predicting a suﬃcient SVR rate [16]. As
an alternative, higher dosages of thiazolidindiones (as com-
pared to the above quoted study) or metformin may be used.
Finally, insulin sensitizing therapy might need to be tailored
according to HCV genotype, and PPARs agonists should
probably be considered only in insulin-resistant patients
with HCV genotype 3a [23]. Finally, interactions of insulin
sensitizing agents with other drugs, most notably those taken
for psychiatric comorbidities, should be considered. In the
quoted study, a paradoxical increase of the HOMA score
was observed in two patients during therapy, and both
patientsweretakingdrugsfortheirpsychiatriccomorbidities
that may also alter insulin sensitivity, that is, zopiclone and
olanzapine. Thus, the beneﬁcial eﬀect of pioglitazone may be
nulliﬁed in patients taking drugs for psychiatric indications.
In addition to the potential eﬀects of these and other drugs,
also the acute administration of IFN-α may induce some
degree of insulin resistance in both healthy subjects [45]a n d
chronic hepatitis C patients [46]. The interactions among
all these drugs are, however, speculative, but require further
studies, in view of the frequent use of antidepressants in
chronic hepatitis C patients. Thus, further clinical trials
aiming at reducing the insulin resistance in chronic hepatitis
C via diﬀerent pharmacological interventions are warranted.
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